Nuzenio

Nanjing Leads Biolabs

Nanjing Leads Biolabs news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Nanjing Leads Biolabs Co., Ltd. (9887.HK) stock price, news, quote and history - Yahoo Finance SingaporeYahoo Finance Singapore · Fri, 07 Aug 2026 06:34:16 GMTNanjing Leads Biolabs Co., Ltd. Advances Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) to Expansion Phase in First-Line Hepatocellular Carcinoma Clinical Study - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 10:52:26 GMTLeads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 01:13:02 GMTLeads Biolabs Wins IND Approval to Test Opamtistomig in Metastatic Colorectal Cancer - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 19:39:16 GMTLeads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases - The Manila TimesThe Manila Times · Tue, 04 Aug 2026 12:18:05 GMTLeads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 03:56:06 GMTNanjing Leads Biolabs Says Lbl-024 Receives IND Approval From NMPA For Metastatic Colorectal Cancer - TradingViewTradingView · Mon, 03 Aug 2026 01:44:00 GMTNanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer - tipranks.comtipranks.com · Sun, 02 Aug 2026 23:56:07 GMT

Timeline

Fri, 07 Aug 2026 06:34:16 GMTNanjing Leads Biolabs Co., Ltd. (9887.HK) stock price, news, quote and history - Yahoo Finance Singapore
Thu, 06 Aug 2026 10:52:26 GMTNanjing Leads Biolabs Co., Ltd. Advances Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) to Expansion Phase in First-Line Hepatocellular Carcinoma Clinical Study - marketscreener.com
Thu, 06 Aug 2026 01:13:02 GMTLeads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals - The Manila Times
Wed, 05 Aug 2026 19:39:16 GMTLeads Biolabs Wins IND Approval to Test Opamtistomig in Metastatic Colorectal Cancer - BioPharm International
Tue, 04 Aug 2026 12:18:05 GMTLeads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases - The Manila Times
Mon, 03 Aug 2026 03:56:06 GMTLeads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise - The Manila Times

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Nanjing Leads Biolabs.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.